Skip to main content
Top
Published in: Discover Oncology 4/2010

01-08-2010

Breast Ductal Lavage for Assessment of Breast Cancer Biomarkers

Authors: Robert Treat Chatterton Jr., Noah P. Parker, Mito Habe-Evans, Michele Bryk, Denise M. Scholtens, Seema A. Khan

Published in: Discover Oncology | Issue 4/2010

Login to get access

Abstract

Lavage of the ductal systems of the breast provides fluid (ductal lavage fluid, DLF) containing hormones and products of hormone actions that may represent more accurately the composition of the breast than samples collected from blood or urine. The present study was undertaken to assess the presence of potential cancer biomarkers, their variation among individuals at high risk for breast cancer, and differences associated with menopause and tamoxifen treatment. Seventy seven tamoxifen-eligible subjects with a 5-year breast cancer risk estimate (Gail > 1.6%; N = 53) or recently diagnosed breast cancer (N = 24) were offered tamoxifen therapy; those not accepting tamoxifen were under observation only. After 6 months, all subjects underwent ductal lavage (DL) in an unaffected breast. Estradiol (E2), estrone sulfate, androstenedione, dehydroepiandrosterone (DHEA), DHEA sulfate, progesterone, cathepsin D, and epidermal growth factor (EGF) were measured in ductal lavage fluid (DLF) by immunoassays. Data were expressed as the mass of analyte per milligram of protein in DLF and normalized by natural log transformation. With the exception of DHEA, none of the analytes measured were significantly lower in postmenopausal women than in premenopausal women. The mean loge concentration difference in estradiol was 10.9%. Tamoxifen treatment for 6 months did not result in a significantly greater concentration of E2 or in any of the other analytes in DLF of pre- or postmenopausal women. The between-duct variance of the concentration of free steroids within the same breast averaged 51% less than that between subjects, and was similar to that of non-diffusible proteins. The maintenance of estradiol concentrations in the breast after menopause demonstrates the importance of local biosynthesis. The fact that DLF E2 does not reflect the high serum concentrations of E2 during tamoxifen treatment indicates that breast concentrations of estradiol may be under feedback control. Unlike studies of low risk populations, progesterone concentrations were not significantly less in postmenopausal than in premenopausal women. The similarity in variance of free steroids and protein analytes between ducts of a breast indicates little transfer of steroids between lobules.
Literature
1.
go back to reference Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3(1):49–61CrossRefPubMed Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3(1):49–61CrossRefPubMed
2.
go back to reference Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415CrossRefPubMed Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415CrossRefPubMed
3.
go back to reference Hankinson SE, Eliassen AH (2010) Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 1:2–10CrossRef Hankinson SE, Eliassen AH (2010) Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 1:2–10CrossRef
4.
go back to reference Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856–1865CrossRefPubMed Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856–1865CrossRefPubMed
5.
go back to reference Chatterton RT Jr, Geiger AS, Gann PH, Khan SA (2003) Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 86:159–166CrossRefPubMed Chatterton RT Jr, Geiger AS, Gann PH, Khan SA (2003) Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 86:159–166CrossRefPubMed
6.
go back to reference Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH (2004) Variation in estradiol, estrogen precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomark Prev 13(6):928–935 Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH (2004) Variation in estradiol, estrogen precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomark Prev 13(6):928–935
7.
go back to reference Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH (2004) Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 90:1686–1691CrossRefPubMed Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH (2004) Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 90:1686–1691CrossRefPubMed
8.
go back to reference Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT (2006) Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins. Cancer Epidemiol Biomark Prev 15(1):39–44CrossRef Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT (2006) Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins. Cancer Epidemiol Biomark Prev 15(1):39–44CrossRef
9.
go back to reference Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86(3–5):245–253CrossRefPubMed Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86(3–5):245–253CrossRefPubMed
10.
go back to reference Blankenstein MA, Szymczak J, Daroszewski J, Milewicz A, Thijssen JH (1992) Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol Endocrinol 6(1):13–17CrossRefPubMed Blankenstein MA, Szymczak J, Daroszewski J, Milewicz A, Thijssen JH (1992) Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol Endocrinol 6(1):13–17CrossRefPubMed
11.
go back to reference Thijssen JH, van Landeghem AA, Poortman J (1986) Uptake and concentration of steroid hormones in mammary tissues. Ann NY Acad Sci 464:106–116CrossRefPubMed Thijssen JH, van Landeghem AA, Poortman J (1986) Uptake and concentration of steroid hormones in mammary tissues. Ann NY Acad Sci 464:106–116CrossRefPubMed
12.
go back to reference Thijssen JH, Blankenstein MA, Miller WR, Milewicz A (1987) Estrogens in tissues: uptake from the peripheral circulation or local production. Steroids 50(1–3):297–306CrossRefPubMed Thijssen JH, Blankenstein MA, Miller WR, Milewicz A (1987) Estrogens in tissues: uptake from the peripheral circulation or local production. Steroids 50(1–3):297–306CrossRefPubMed
13.
go back to reference Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41CrossRefPubMed Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41CrossRefPubMed
14.
go back to reference Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J, Milewicz A, Thijssen JH (1992) On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 41(3–8):891–896CrossRefPubMed Blankenstein MA, Maitimu-Smeele I, Donker GH, Daroszewski J, Milewicz A, Thijssen JH (1992) On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 41(3–8):891–896CrossRefPubMed
15.
go back to reference Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27CrossRefPubMed Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27CrossRefPubMed
16.
go back to reference Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643CrossRefPubMed Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A (1997) Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 70(6):639–643CrossRefPubMed
17.
go back to reference Dooley WC, Ljung B-M, Veronesi U, Cassaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624–1632CrossRefPubMed Dooley WC, Ljung B-M, Veronesi U, Cassaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624–1632CrossRefPubMed
18.
go back to reference Bhandare D, Nayar R, Bryk M, Hou N, Cohn R, Golewale N, Parker NP, Chatterton RT, Rademaker A, Khan SA (2005) Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomark Prev 14(11):2620–2627CrossRef Bhandare D, Nayar R, Bryk M, Hou N, Cohn R, Golewale N, Parker NP, Chatterton RT, Rademaker A, Khan SA (2005) Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomark Prev 14(11):2620–2627CrossRef
19.
go back to reference Love SM (2005) Re: ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 97(11):857–858PubMed Love SM (2005) Re: ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 97(11):857–858PubMed
20.
go back to reference Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488–1491CrossRefPubMed Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488–1491CrossRefPubMed
21.
go back to reference Groom GV, Griffiths K (1976) Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70(3):421–428CrossRefPubMed Groom GV, Griffiths K (1976) Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70(3):421–428CrossRefPubMed
22.
go back to reference Kostoglou-Athanassiou I, Ntalles K, Gogas J, Markopoulos C, Evizou-Terzaki V, Athanassiou P, Georgiou E, Proukakis C (1997) Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm Res 47(3):116–120CrossRefPubMed Kostoglou-Athanassiou I, Ntalles K, Gogas J, Markopoulos C, Evizou-Terzaki V, Athanassiou P, Georgiou E, Proukakis C (1997) Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm Res 47(3):116–120CrossRefPubMed
23.
go back to reference Gail MH (2001) The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann NY Acad Sci 949:286–291CrossRefPubMed Gail MH (2001) The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann NY Acad Sci 949:286–291CrossRefPubMed
24.
go back to reference Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, Ivancic D, Nayar R, Masood S, Rademaker A (2009) Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res 2(3):265–273CrossRef Khan SA, Lankes HA, Patil DB, Bryk M, Hou N, Ivancic D, Nayar R, Masood S, Rademaker A (2009) Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res 2(3):265–273CrossRef
26.
go back to reference Couissi D, Dubois V, Remacle C, Schonne E, Trouet A (1997) Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182, 780. Clin Exp Metastasis 15(4):349–360CrossRefPubMed Couissi D, Dubois V, Remacle C, Schonne E, Trouet A (1997) Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182, 780. Clin Exp Metastasis 15(4):349–360CrossRefPubMed
27.
go back to reference Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548CrossRefPubMed Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548CrossRefPubMed
28.
go back to reference Gingras S, Cote S, Simard J (2000) Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. Mol Endocrinol 14(2):229–240CrossRefPubMed Gingras S, Cote S, Simard J (2000) Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. Mol Endocrinol 14(2):229–240CrossRefPubMed
29.
go back to reference Purohit A, Singh A, Reed MJ (1999) Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer. Biochem Soc Trans 27(2):323–327PubMed Purohit A, Singh A, Reed MJ (1999) Regulation of steroid sulphatase and oestradiol 17 beta-hydroxysteroid dehydrogenase in breast cancer. Biochem Soc Trans 27(2):323–327PubMed
30.
go back to reference Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ (2006) The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 248(1–2):199–203CrossRefPubMed Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ (2006) The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 248(1–2):199–203CrossRefPubMed
31.
go back to reference Going JJ (2006) Ductal-lobar organisation of human breast tissue, its relevance in disease and a research objective: vector mapping of parenchyma in complete breasts (the Astley Cooper project). Breast Cancer Res 8(4):107–107CrossRefPubMed Going JJ (2006) Ductal-lobar organisation of human breast tissue, its relevance in disease and a research objective: vector mapping of parenchyma in complete breasts (the Astley Cooper project). Breast Cancer Res 8(4):107–107CrossRefPubMed
Metadata
Title
Breast Ductal Lavage for Assessment of Breast Cancer Biomarkers
Authors
Robert Treat Chatterton Jr.
Noah P. Parker
Mito Habe-Evans
Michele Bryk
Denise M. Scholtens
Seema A. Khan
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Discover Oncology / Issue 4/2010
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-010-0021-y

Other articles of this Issue 4/2010

Discover Oncology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine